Kiniksa Pharmaceuticals International, PLC

Kiniksa Pharmaceuticals announced robust second quarter 2026 financial results, driven by significant growth in ARCALYST net product revenue and positive clinical trial updates for KPL-387.

Kiniksa Pharmaceuticals confirms the re-election of three directors and the ratification of PwC as auditors following its 2026 Annual Meeting.

Kiniksa Pharmaceuticals International, plc has entered into a deed of waiver with Baker Bros. Advisors LP, impacting conversion rights of certain shareholders.

Kiniksa Pharmaceuticals Chief Strategy Officer Eben Tessari will resign effective May 15, 2026, to transition into a consulting and advisory role.

Kiniksa Pharmaceuticals announced robust first quarter 2026 financial results, driven by significant growth in ARCALYST net product revenue and an increased full-year revenue guidance.

Kiniksa Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant ARCALYST sales growth and a positive outlook for 2026.

Kiniksa Pharmaceuticals International, plc announced robust Q2 2026 financial results, driven by significant growth in ARCALYST net revenue and continued investment in pipeline development.

Kiniksa Pharmaceuticals reported strong third-quarter 2025 financial results, driven by significant ARCALYST revenue growth and a shift to net income from a prior-year loss.

Kiniksa Pharmaceuticals International, plc announced a significant increase in product revenue and a return to net income for the second quarter and first half of 2025, primarily driven by robust ARCALYST sales and progress in its KPL-387 clinical program.

Kiniksa Pharmaceuticals announces a profitable first quarter in 2025, driven by significant growth in ARCALYST sales and strategic financial management.

Kiniksa Pharmaceuticals reports a significant increase in Q3 revenue, primarily driven by strong sales of ARCALYST, while also detailing ongoing clinical development and strategic collaborations.

Kiniksa Pharmaceuticals reports a significant increase in product revenue for the second quarter of 2024, alongside ongoing strategic initiatives including a manufacturing technology transfer.

Kiniksa Pharmaceuticals International, plc reported significant product revenue growth in 2025, driven by ARCALYST sales, while advancing its pipeline with KPL-387 and KPL-1161.

Kiniksa Pharmaceuticals reported a net loss for 2024, driven by increased operating expenses, despite significant revenue growth from its lead asset, ARCALYST.

Kiniksa Pharmaceuticals reports its full year 2023 financial results, showcasing revenue growth and advancements in its clinical programs.

G Bradley Cole, a Director of Kiniksa Pharmaceuticals International, plc, sold 3,673 shares of common stock on July 29, 2026 for $81.43 per share.

Dhiraj H. Malkani, Chief Strategy Officer at Kiniksa Pharmaceuticals, was granted stock options and restricted share units on July 1, 2026.

Barry D. Quart, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including the acquisition of shares through vested Restricted Stock Units and the exercise of stock options.

Director Kimberly J. Popovits reported transactions involving Class A Ordinary Shares and stock options for Kiniksa Pharmaceuticals International, plc.

Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals, reported a significant transaction involving Class A and Class B Ordinary Shares.

Tracey L. McCain, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including the acquisition of shares and the vesting of options and restricted stock units.

Kiniksa Pharmaceuticals International, plc has scheduled its 2026 Annual Meeting of Shareholders for May 29, 2026, to address director re-elections, auditor appointments, and executive compensation.

Kiniksa Pharmaceuticals International, PLC is urging shareholders to approve two critical proposals at its upcoming Annual Meeting to grant the Board authority to allot shares and disapply pre-emptive rights, citing competitive disadvantages against US-domiciled companies if not approved.

Kiniksa Pharmaceuticals issues a supplement to its definitive proxy statement to correct errors in the Summary Compensation Table related to certain components of Chief Commercial Officer Ross Moats' compensation.

Kiniksa Pharmaceuticals International, PLC has scheduled its Annual General Meeting for June 3, 2025, and is providing shareholders with proxy materials for voting on key proposals.

Kiniksa Pharmaceuticals International, plc will hold its 2025 Annual Meeting of Shareholders on June 3, 2025, to vote on director elections, auditor appointments, executive compensation, and other corporate matters.

Kiniksa Pharmaceuticals is reminding shareholders to vote for both the Annual General Meeting and the Special Court-Ordered Meeting scheduled for June 5, 2024.

Baker Bros. Advisors LP and affiliated entities have waived their right to convert certain shares into Class A ordinary shares of Kiniksa Pharmaceuticals International, plc, to maintain beneficial ownership below 49.9%.

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 14.8% in Kiniksa Pharmaceuticals International PL's Class A Common Stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Kiniksa Pharmaceuticals International Plc following an internal realignment.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 10.6% beneficial ownership stake in Kiniksa Pharmaceuticals International PL's Class A Common Stock.

The Vanguard Group has reported a 7.04% beneficial ownership stake in Kiniksa Pharmaceuticals International Plc common stock as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.0% beneficial ownership stake in Kiniksa Pharmaceuticals International, plc, totaling 418,151 common shares.

Rubric Capital Management LP and David Rosen have disclosed a beneficial ownership of 9.24% of Kiniksa Pharmaceuticals International, plc's Class A Ordinary Shares.